Background
Determining the predictors of the need for noninvasive ventilation (NIV) in patients with acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is important for identifying factors that could lead to specific treatments and detecting patients in whom pivotal therapeutic interventions should be performed. Objective Evaluate the possible use of procalcitonin (PCT) in the prediction of the severity of AECOPD and its importance on the planning of NIV treatment and to evaluate other possible predictors. Patients and methods This study is a prospective observational study that included 80 patients with chronic obstructive pulmonary disease (COPD) and 18 healthy control persons. PCT level, C reactive protein (CRP), ESR, complete blood count (CBC), arterial blood gas, PFT, and chest radiograph were performed for all studied cases. Bacteriological evaluation of sputum and culture was performed for COPD patients.
Results NIV was used in 24 COPD patients. By regression analysis, high PCT level with a cut-off value of 1.1 ng/ml was a significant predictor to start NIV in AECOPD patients [odds ratio (OR) 3.067; 95% confidence interval (CI)=1.140-4.821; P<0.001 with Introduction Chronic obstructive pulmonary disease (COPD) is a lung disease characterized by chronic obstruction of lung airflow that disables the normal breathing; about 251 million cases of COPD were recorded globally in 2016, and it is estimated that COPD will become the third most frequent cause of death worldwide by 2020 [1] . Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is a sudden worsening of COPD symptoms that typically lasts for several days; it has a serious effect on morbidity, mortality and quality of life and leads to frequent hospitalization [2] . Noninvasive mechanical ventilation (NIV) is considered as a cornerstone management of AECOPD: it can reduce the need for intubation and can improve short-term survival in AECOPD patients [3] . The use of NIV results in the respiratory muscles' unloading, improvement of dyspnea, increased alveolar ventilation, reduction of respiratory rate, and improvement of arterial oxygenation, hypercapnia, and related respiratory acidosis [4] . Hence, it is of great value to find predictors for the need of NIV to treat AECOPD, which can help in making therapeutic decisions.
Most of the previous studies investigated clinical and some
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Procalcitonin (PCT) is a 116 amino-acid peptide with no hormonal activity that is produced by the response to endotoxin and other mediators that are released during bacterial infections, and it is accepted as one of the biomarkers of bacterial infection in many systemic infections such as lower respiratory tract infections and COPD exacerbations [7] . Recently, a lot of studies investigated new predictors for NIV in AECOPD, such as PCT and rapid shallow breathing index [8, 9] . The objective of this study is to investigate the possible use of PCT in the prediction of the severity of AECOPD and its importance in the planning of NIV treatment and, also, to investigate other possible predictors of severe AECOPD.
Patients and methods

Patients
This was a prospective observational case-control study that had been carried out on 98 patients at the Chest Department, Minia University Hospital, Minia Governorate, Egypt, during the period spanning between October 2016 and May 2017. The study included 80 patients with the clinical and functional diagnosis of COPD based on GOLD guidelines [10] . Fifty of the COPD patients were found to have acute exacerbation, and the other 30 patients had stable COPD; the other 18 patients were healthy controls. We excluded patients with congestive heart failure, patients with pulmonary diseases other than COPD (bronchial asthma, pneumonia, bronchiectasis, tuberculosis and other chronic pulmonary disease), sepsis, pulmonary and extrapulmonary malignancies and any diseases that cause an increase in serum PCT levels; the patients received antibiotics within 10 days of admission. Informed consent was obtained from either the patients themselves or their relatives.
All participants were subjected to the following (and they are): history taking from patients or their relatives, detailed general and local chest examination, plain chest radiograph (PA view), and arterial blood gas analysis in addition to the following (and they are):
(1) Spirometry: Spirometry was performed using a spirometer (ZAN 300; nSpire Health Inc 1830 lefthand Circle, Longmont, Colorado, 80501, USA), as the best of three consecutive readings within 100 ml, according to the American Thoracic Society Standards, before and 10 min after inhaled salbutamol 200 mcg. Postbronchodilator ratio less than 70 confirmed the presence of airway limitation and hence COPD. For COPD patients with acute exacerbation, spiromtetric evaluation of the last outpatient clinic was obtained.
(2) Routine laboratory investigations: These included complete blood count (CBC), renal and liver function tests, ESR, and C reactive protein (CRP). CRP in serum was measured semiquantitatively using (GPL Germany kit) according to the manufacturer protocol. (3) Serum PCT: PCT was measured in the serum by using ELISA according to the human PCT ELISA kit (Glory Science Co. Ltd, Hangzhou, Zhejiang, China) protocol. PCT level less than 0.1 indicated that bacterial infection was highly unlikely, 0.1 to less than 0.25 indicated unlikely bacterial infection, 0.25 to less than 0.5 indicated likely bacterial infection and more than 0.5 also indicated likely bacterial infection. (4) Bacteriological evaluation of sputum and culture:
Gram stain was performed, and sputum quality was assessed; the presence of more than 25 polymorphonuclear leukocytes and less than 10 squamous epithelial cells per low-power field in Gram-stained sputum was synonymous with representative sputum. Representative sputum samples were cultured. Bacterial infection was defined as potential pathogen presence in the sample of representative sputum.
Criteria of NIV were as follows [1] : respiratory distress (moderate to severe dyspnea, using of accessory muscles of respiration or abdominal paradox) [2] , acute respiratory failure [low arterial PH (<7.35) with hypercapnia (>45 mmHg)] [3] , and high respiratory rate (>24 breaths/ml) [11] . COPD severity was defined as mild when the postbronchodilator forced expiratory volume in the first second (FEV 1 ) was at least 80% predicted, moderate when postbronchodilator FEV 1 ranged from 50 to 79% predicted, severe when postbronchodilator FEV 1 ranged from 30 to 49% predicted, and very severe when postbronchodilator FEV 1 was less than 30% predicted [10] .
AECOPD definition: acute worsening of respiratory symptoms; an increase in the amount and purulence of sputum, and gradually worsening dyspnea that results in additional therapy [12] . Anthonisen criteria were used to evaluate the type of exacerbation. The presence of all of the following criteria such as an increase in the severity of dyspnea [based on modified medical research council (mMRC)], purulence of sputum and amount of the sputum were used to define type 1 exacerbation. Type 2 exacerbation required the presence of two of these symptoms. The presence of one of these symptoms plus upper respiratory tract infection, fever, and an increase in the severity of wheezing and cough, and 20% increase in the respiratory rate and heart rate within the previous 5 days were used to define type 3 AECOPD [12] .
Statistical analysis
Data entry and analysis were carried out using SPSS (statistical program for social science, version 17, SPSS Inc., Chicago, IL). The following statistical methods were used: description of quantitative variables as mean ±SD, and ranges; description of qualitative variables as numbers and percentages; χ 2 -test for comparisons of qualitative variables between groups; unpaired t-test to compare between the two groups in continuous variables; and Pearson and Spearman's correlation coefficients to rank different variables as either positive or inverse. For the establishment of PCT cut-off value so as to make a distinction between cases treated with or without non-invasive positive pressure ventilation (NPPV), receiver operating characteristic analysis was performed, and area under the curve was calculated. Univariate Cox regression was used for analysis of risk factors for the need to initiate noninvasive ventilation (NIV). The results were considered to be statistically significant at a P value less than 0.05, highly significant at a P value less than 0.01, and insignificant at a P value more than 0.05.
Ethical considerations
The study was approved by Minia University Hospital's Research Ethics Board, Minia University, Egypt.
Results
This study included 80 COPD patients: 50 of them had AECOPD, and the other 30 patients had stable COPD, in addition to 18 healthy patients who served as a control group. The mean age of COPD patients was 63.15±9.1 years, and 81.2% of them were male individuals and 77.5% were smokers. Postbronchodilator FEV 1 was 39.2±15.7, which was significantly lower than that of healthy individuals, like other parameters of spirometry. COPD patients were significantly more hypoxic, more hypercapneic and had a significantly higher concentration of white blood cells (WBCs), neutrophils, urea, ESR, CRP, and PCT in comparison with the healthy control group. Moreover, AECOPD patients had significantly lower values of spirometry, lower values of PO 2 and PCO 2 and had significantly higher values of SaO 2 , WBCs, neutrophils, ESR, CRP, PCT and higher positive sputum culture compared with the stable COPD group. Following admission of AECOPD patients, 24 (48%) patients received NIV; these patients who underwent NIV had significantly lower values of spirometry than those without NIV. They were significantly more acidotic, more hypoxic, more hypercapneic and had significantly higher WBCs, neutrophils, urea, ESR, CRP and PCT levels in comparison with those without NIV (Tables 1 and 2) . Table 3 shows that serum PCT levels differed in terms of types and severity of AECOPD, and the highest level was determined in severe exacerbation. There was almost a significant difference among all classes of severity and types of exacerbation. (Table 5) . At a cut-off value of 1.1 ng/ml, PCT had 95.8% sensitivity and 99% specificity for predicting AECOPD patients who needed ventilatory support; the area under the curve was 0.94 ( Table 6 and Figure 1 ).
Discussion
The aim of this study was to evaluate the predicton of NIV in patients with AECOPD, with a special interest for the effect of PCT and other inflammatory markers. Determining the predictors of the need for NIV in AECOPD patients is important to identify factors that can lead to specific treatments and detect patients in whom more powerful therapeutic interventions should be performed. To achieve this aim, we included three groups in this investigation: a group of 50 patients with AECOPD, group of 30 patients with stable COPD and a group of 18 healthy persons as a control group; NIV was administered for 24 patients with AECOPD. In this study, serum PCT levels were significantly higher in the COPD patients' group (0.82±0.5 ng/ ml) compared with the control group (0.30±0.07 ng/ ml). This is similar to the results of Mohamed et al. [13] who found that the PCT level was significantly higher in COPD patients than in healthy patients. Moreover, we found that serum PCT levels were significantly higher in the AECOPD patients' group (1.12±0.4 ng/ml) than in the stable COPD patients' group (0.31±0.14 ng/ml). This result is supported by Pazarli et al. [14] .
In this study, the majority of our patients with AECOPD had a bacterial infection (94%), while fungal infection was present in 6% of the patients. The causative microbes among AECOPD patients were as follows: Gram-positive bacteria caused exacerbation in 72% of the patients, while Gramnegative bacteria were the cause in 22%; however, candidiasis was the cause in 6% of the patients. Streptococcus spp. was the most common organism (36%), followed by MRSA (18%), Staphylococcus spp. (18%), Pseudomonas spp. (12%), and Klebsiella spp. (10%). Soler et al. [15] reported that the microbiological pattern among AECOPD patients matched with community-acquired organisms: Streptococcus pneumoniae, Hemophillus influenzae, and Moraxella catarrhalis in 56%, and Gram-negative enteric bacilli, pseudomonas, and Stenotrophomonas spp. in 44% of isolates; however, other organisms such as Clostridium pneumoniae and respiratory viruses were found in 18 and 16% of patients. In another recent study, it was reported that the most common bacteria in AECOPD patients were H. influenza (23.9) and Pseudomonas aeruginosa (14.1%) [17] reported that serum PCT levels were significantly greater in patients infected with Gram-negative than in those infected with Gram-positive organisms. In another study, by Koivula et al. [18] , they found that high levels of PCT within 24 h after the onset of fever predicted Gram-negative bacteremia in patients with hematological diseases. Furthermore, Brodská et al. [19] found that the PCT cut-off value of 15 ng/ml can differentiate sepsis caused by Gram-negative or by Gram-positive organisms and fungi, with a specificity of 87.8%. Müller et al. [20] found that laboratory parameters, such as CRP level and leukocyte counts, were less valuable for early diagnosis of bacterial infection than PCT, which can be used to identify bacterial infections in AECOPD patients.
In this study, it was found that the levels of systemic inflammatory markers (PCT, CRP, ESR, WBCs count and neutrophils count) were significantly higher in the AECOPD group than in the stable COPD group. Similar to our findings, Zhang and Zhou [21] , found that the levels of CRP, PCT, and WBC and neutrophil counts, in the infective COPD group were significantly higher than those in the noninfective group (P<0.05 or <0.01) before treatment, and the levels of PCT and CRP, and ESR, and WBC and neutrophil counts after treatment were much lower than those before treatment. In addition, Weis and Almdal [22] in their study recorded an increased CRP level in patients with AECOPD due to bacterial infections. We found a significantly positive correlation between PCT level and other markers of inflammation, such as high temperature, CRP, ESR (first and second hour), WBC and neutrophil count in COPD patients (either during stable condition or during exacerbation). This is in agreement with Mohamed et al. [13] and Pazarli et al. [14] who concluded that PCT has a significant positive correlation with CRP, ESR, WBC count and temperature, and this suggests that these inflammatory markers including PCT increase the predictive value in identifying bacterial infection.
With regard to the relation between PCT and the severity of AECOPD, the results revealed an increased level of PCT with the severity of AECOPD (as graded by Anthonisen criteria, P=0.03). This is supported by a study carried out by Stolz et al. [23] ; they evaluated 167 AECOPD cases according to the Anthonisen classification, and higher levels of PCT were determined in type 1 AECOPD than in other types; they added that PCT levels of patients who required ICU admission were also found to be higher than others. Moreover, Pazarli et al. [14] found that PCT levels differed in terms of severity of AECOPD, and higher levels were determined in severe exacerbation. In addition, we noticed that the PCT level increased with increased airflow limitation, as graded by GOLD severity (P=0.001). Furthermore, our study recorded a negative correlation between PCT and postbronchodilator FEV 1 in COPD patients who were either stable patients or patients with AECOPD (p 0.001). This is in accordance with Daubin et al. [24] , who reported higher PCT levels in patients with very severe exacerbation. Hurst et al. [25] reported that systemic biomarkers were not helpful in predicting the severity of AECOPD.
In this study, the results of univariate Cox regression analysis revealed that old predictors including low PaO 2 , high PaCO 2 , low FEV 1 , high WBCs, high neutrophil count, high ESR, and high CRP were significant predictors associated with the need to initiate NIV; moreover, high serum PCT level (a new predictor) was also found to be a significant predictor of the need for NIV in AECOPD patients. In agreement with this study, Bolton and Bleetman [26] recommended that patients with AECOPD with respiratory acidosis potential hydrogen (pH) less than 7.35 and PaCO 2 more than 45 mmHg or PaO 2 less than 60 mmHg should receive NIV. In addition, Taga et al. [27] reported that high PaCO 2 and low FEV 1 are significant predictors of NIV in patients with AECPOD by using univariate Cox proportional hazards analysis.
As shown in our results, PCT level was found to be statistically higher in patients with AECOPD who needed NIV than those who did not (1.48±0.25 vs. 0.81±0.37 ng/ml, respectively). Moreover, in a cutoff of 1.1 ng/ml, PCT had 95.8% sensitivity and 99% specificity for predicting AECOPD patients who needed NIV. Similar to our findings, Pazarli et al. [14] also reported that PCT was significantly higher in patients with AECOPD treated with NIV (0.36±0.26 ng/ml) than in those not treated with NIV (0.15±0.16 ng/ml), and they also found that a cut-off value for PCT for predicting need for NIV therapy was found to be higher than 0.1 ng/ ml. El Halim et al. [28] found a significant difference between AECOPD patients who needed NIV and those did not (2.02±0.56 vs. 1.262±0.39 ng/ml, respectively). The cut-off value of PCT for predicting the need for ventilatory support was 1.495 ng/ml, with 85.7% sensitivity and 78.3% specificity. Furthermore, Rammaert et al. [29] found that higher PCT levels in severe AECOPD cases were associated with the need for NIV and ICU mortality.
Conclusion
On the basis of our results, AECOPD patients had high PCT levels, and this suggests its role in predicting bacterial infections, the reflection of the severity of infection, discrimination between bacterial and nonbacterial exacerbation and in predicting the need for NIV. In addition, the results revealed that the PCT cut-off value of at least 1.1 ng/ml could suggest the need for NIV with high sensitivity and specificity. The present study strongly recommends the use of PCT in predicting bacterial AECOPD, and the need for NIV. The limitation of our study is the limited number of included patients; hence, further larger prospective studies are warranted.
